These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33008495)

  • 21. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The evolving role of immunotherapy in prostate cancer.
    Gerritsen WR
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent progress in immunotherapy for urological cancer.
    Obara W; Kato R; Kato Y; Kanehira M; Takata R
    Int J Urol; 2017 Oct; 24(10):735-742. PubMed ID: 28636222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Not Available].
    Oudard S; Thibault C; Angelergues A; Tartour E; Timsit MO; Mejean A; Michel C; Vano Y
    Bull Cancer; 2016 Nov; 103 Suppl 1():S144-S150. PubMed ID: 28057178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapeutic approaches in prostate cancer: combinations and clinical integration.
    Slovin SF
    Am Soc Clin Oncol Educ Book; 2015; ():e275-83. PubMed ID: 25993186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer.
    Wesley JD; Whitmore J; Trager J; Sheikh N
    Hum Vaccin Immunother; 2012 Apr; 8(4):520-7. PubMed ID: 22370520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy for Prostate Cancer.
    Venturini NJ; Drake CG
    Cold Spring Harb Perspect Med; 2019 May; 9(5):. PubMed ID: 30201787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
    Dawson NA; Roesch EE
    Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate cancer: any room left for immunotherapies?
    Baxevanis CN; Fortis SP; Perez SA
    Immunotherapy; 2019 Feb; 11(2):69-74. PubMed ID: 30727800
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunotherapy: a glimmer of hope for metastatic prostate cancer.
    Jindal V
    Chin Clin Oncol; 2018 Dec; 7(6):61. PubMed ID: 29860848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer immunotherapy.
    Mitsogiannis I; Tzelves L; Dellis A; Issa H; Papatsoris A; Moussa M
    Expert Opin Biol Ther; 2022 May; 22(5):577-590. PubMed ID: 35037527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
    Lü C; Williams AK; Chalasani V; Martínez CH; Chin J
    Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy for prostate cancer: walk, don't run.
    Drake CG
    J Clin Oncol; 2009 Sep; 27(25):4035-7. PubMed ID: 19635998
    [No Abstract]   [Full Text] [Related]  

  • 37. Chemotherapy and immunotherapy combination in advanced prostate cancer.
    Slovin S
    Clin Adv Hematol Oncol; 2012 Feb; 10(2):90-100. PubMed ID: 22402350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer.
    Nair SS; Weil R; Dovey Z; Davis A; Tewari AK
    Urol Clin North Am; 2020 Nov; 47(4S):e17-e54. PubMed ID: 33446323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress in active specific immunotherapy of prostate cancer.
    Tjoa BA; Murphy GP
    Semin Surg Oncol; 2000; 18(1):80-7. PubMed ID: 10617899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Melanoma: is immunotherapy of benefit?
    Faries MB; Morton DL
    Adv Surg; 2003; 37():139-69. PubMed ID: 12953631
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.